Wednesday, July 8, 2026

pharma · Dravet Syndrome · Dravet syndrome · STOK

Stoke Therapeutics

Stoke Therapeutics is a pharma organization headquartered in Bedford, USA. It trades on NYSE under ticker STOK. Primary therapeutic focus areas include Dravet Syndrome, Dravet syndrome, Autosomal Dominant Optic Atrophy,

Bedford, USA HQ
2017 Founded
205 Employees
Public company Type
STOK · NYSE Ticker
Company details
Status
Public
HQ
Bedford, USA
Founded
2017
Employees
205
Programs
8
Drugs
4
Patents
14
Clinical program

Transanal irrigation with Peristeen Anal Irrigation

Approved · other · Constipation

Transanal irrigation with Peristeen Anal Irrigation for Constipation is a Approved program (other) at Stoke Therapeutics with 1 ClinicalTrials.gov record(s).

← All Stoke Therapeutics projects Approved other completed

Internal code DK021CC

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Stoke Therapeutics
Phase
Approved
Modality
other
Indication
Constipation
Status
completed
Trials
1